



## **DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference**

June 1, 2022

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:30 p.m. ET.

A live and archived webcast of the presentation can be accessed under "Events & Presentations" on the Investors section of the Company's website. The archived webcast will be available on the Company's website for 90 days after the event.

### **About DICE Therapeutics, Inc.**

DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company's DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE's lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting  $\alpha4\beta7$  integrin and  $\alpha V\beta1/\alpha V\beta6$  integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

### **Contact:**

Katie Engleman, 1AB  
katie@1abmedia.com